Journal of Clinical Medicine (May 2022)

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

  • Luisa Agnello,
  • Bruna Lo Sasso,
  • Matteo Vidali,
  • Concetta Scazzone,
  • Caterina Maria Gambino,
  • Tommaso Piccoli,
  • Giulia Bivona,
  • Anna Maria Ciaccio,
  • Rosaria Vincenza Giglio,
  • Vincenzo La Bella,
  • Marcello Ciaccio

DOI
https://doi.org/10.3390/jcm11113139
Journal volume & issue
Vol. 11, no. 11
p. 3139

Abstract

Read online

(1) Background: Alpha-synuclein (α-syn) is a presynaptic neuronal protein that regulates several neuronal functions. In recent decades, the role of α-syn as a biomarker of neurodegenerative diseases has been explored, especially in synucleinopathies. However, only a few studies have assessed its role as biomarker in other neurological disorders. The aim of the study was to evaluate cerebrospinal fluid (CSF) α-syn levels in several neurological disorders; (2) Methods: We measured CSF α-syn levels by a commercial ELISA kit in 158 patients classified in the following group: controls, Alzheimer’s Disease (AD), cerebrovascular diseases, inflammatory central nervous system diseases, other neurological diseases, Parkinson’s Disease (PD), and peripheral neuropathy; (3) Results: Patients with PD showed the lowest and patients with AD the highest levels of CSF α-syn (1372 vs. 2912 pg/mL, respectively, p < 0.001). In AD patients, α-syn levels were significantly associated with tau proteins; (4) Conclusions: α-syn could represent a biomarker of neurodegenerative diseases.

Keywords